The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers:π½ππΎπΌ1/2
β’ Consider breast-conserving therapy
β’ Consider nipple-sparing mastectomy, if medically appropriate
β’ Advanced breast cancer:
β«Έ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy
β«Έ Platinum agents are recommended versus taxanes
ππ53
β’ Mastectomy is advised
β’ Radiation therapy is contraindicated except for those at risk for locoregional recurrence
For more information, check out the full article at: https://ascopubs.org/doi/full/10.1200/JCO.20.00299